🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are on the rise globally, with data suggesting over 82 million new cases each year. Especially elevated rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The World Health Organization has listed it as a "priority pathogen". A tracking program found that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Authorization

Zoliflodacin, also known as a brand name, was approved by the US FDA in mid-December for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists hope that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This drug, which is employed against urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This milestone marks a significant shift in the management of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Testing Results and Worldwide Availability

As per data released by a major medical journal, the new drug eradicated more than 90% of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which involves a dual-drug approach. The research included hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the ability to license and sell the drug in many regions with limited resources.

Clinicians treating patients have expressed optimism. The availability of a easy-to-administer therapy such as this is described as a "revolutionary step" for managing the epidemic. This is viewed as crucial to alleviate the strain of the disease for people and to prevent the spread of highly drug-resistant gonorrhoea around the world.